Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

SmartClot: Personalized platform for the combined evaluation of platelet and coagulation factor in haemostasis or during antithrombbotic therapy

Project description

Better-informed therapy against thrombosis

Thrombosis – the development of blood clots in veins or arteries – is a dangerous condition that can lead to blocked blood flow and eventually to life-threatening emergencies such as heart attack. Venous ultrasounds or CT angiography scans are used to diagnose thrombosis, while platelet aggregation and function tests are employed to monitor the efficacy of antiplatelet therapy and to potentially identify the condition. The EU-funded Smart Clot project has developed a cutting-edge technology for monitoring coagulation and platelet function. It is automated and easy to use, providing both quantitative and qualitative multiparametric data. Implementation of the platform into routine screening will assist thrombosis treatment.

Objective

Today there is a big concern about cardiovascular diseases (CVD); because each year, it causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. With almost 49 million people living with cardiovascular disease in the EU, these problems have a huge impact on public health and on health and economic resources, with a total cost of € 2.10 billion/year. Unfortunately, over the last 25 years the number of cardiovascular diseases cases has increased in Europe. The current medical devices monitor just platelet aggregation or coagulation providing inaccurate estimations and in consequence observing insufficient therapy in thrombosis treatment or excessive therapy dosage in bleeding cases in individual patients. In response, we at SEDICIDODICI have developed, SMART CLOT, a cutting-edge technology for the combined evaluation of coagulation and platelet function for monitoring i) haemostasis (process which causes bleeding to stop, keeping the blood within a damaged blood vessel) as diagnosis tool and ii) antithrombotic treatment to control patients with diseases such as cardiovascular diseases, hypertension, thrombosis, diabetes, pulmonary embolism. It is a user-friendly, automated and real-time platform that provides qualitative/quantitative information based on an instrument and an array of multifunctional flow cartridges designed to interrogate specific pathways of both coagulation and platelet activation under relevant arterial and venous flow conditions. Before reaching market maturity we need in Phase 1 to run a Feasibility Study that helps us organise technical, commercial and financial plan of the project. Finally, SMART CLOT will bring an effective platform for the diagnosis and antithrombotic treatment. SEDICIDODICI will concentrate on the growth of SMART CLOT and in 5 years from launch we expect to earn € 22.3 million in profits, 24 new people and a ROI of 6.08 per euro invested.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

SEDICIDODICI SRL
Net EU contribution
€ 50 000,00
Address
VIA ROVEREDO 20/B
33170 PORDENONE
Italy
SME
Yes
Region
Nord-Est Friuli-Venezia Giulia Pordenone
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00